Arca
Skip to content
Tools
Tools

Biotech Acquisitions

When a company buys a listed biotech, it either offers to buy the shares directly (a tender offer) or the shareholders vote on a merger. Both are filed with the SEC, with the price and the buyer's name.

Who bought whom since 2016: 451 tender offers and mergers for listed drug, device and life-science tools companies, read from their SEC filings, plus private companies bought in deals announced on the wires since Arca began mirroring them.

  • Listed companies bought, last 12 months: 51
  • Their combined value: $177B
  • Still pending: 15
  • Largest, last 12 months: $20B

Listed companies bought per year

By the year the deal was announced.

How to read this

A hatched bar is a year that is not over, so its count covers only part of the year.

  • Full year
  • 2026 to date, through Nov 19, 2026

Deal value per year

Billions of dollars, upfront; contingent value rights are not counted. A few megadeals make most years.

How to read this

A hatched bar is a year that is not over, so its count covers only part of the year.

By disease area, last 3 years

The area most of the bought company's registered trials are in.

Most frequent buyers since 2016

Listed companies bought, and what was paid.

Largest, last 12 months

By deal value.

  • Avidity BiosciencesNovartis AG$11B

Every acquisition

Newest first. Value is the transaction value in the filing-fee table, the value the filing or release states, or the price times the shares outstanding; hover a value for which.

459 acquisitions

Per shareSources
Nov 17, 2026Form BioPrivate companyAstromechNot statedโ€”โ€”PendingPR Newswire
Nov 17, 2026Gallant Pet, Inc.Private companyDechraNot statedโ€”โ€”PendingPR Newswire
Nov 16, 2026Calytrix BioPrivate companyLillyNot statedโ€”HematologyPendingPR Newswire
Nov 16, 2026Contego MedicalPrivate companyMedtronicNot statedโ€”CardiovascularPendingPR Newswire
Nov 16, 2026Ollin BiosciencesPrivate companyJohnson & Johnson$2.2Bโ€”OphthalmologyPendingBusiness Wire
Nov 12, 2026Nexus PharmaceuticalsPrivate companyPAI PharmaNot statedโ€”โ€”PendingPR Newswire
Nov 12, 2026NeuroAirmid Therapeutics, Inc.Private companyLineage Cell Therapeutics, Inc.Not statedโ€”NeurologyPendingBusiness Wire
Nov 10, 2026OmniosePrivate companyAstraZenecaNot statedโ€”Infectious diseasePendingBusiness Wire
Oct 30, 2026Lifecore Biomedical, Inc.Lifecore Inc.$238M$6.28โ€”PendingDEFM14A
Oct 21, 2026Personalis, Inc.Tools and diagnosticsTempus AI, Inc.$1.7B$16.25โ€”PendingDEFM14A
Oct 8, 2026Pacira BioSciences, Inc.Viatris Inc.$1.6B$36.50โ€”Closed Nov 17Schedule TO ยท PR Newswire
Sep 11, 2026Supernus Pharmaceuticals, Inc.Indivior Pharmaceuticals, Inc.Not statedโ€”PsychiatryClosed Nov 2DEFM14A
Sep 4, 2026Biolife Solutions IncMedtechRepligen Corporation$550M$11.25โ€”Closed Oct 6DEFM14A
Sep 4, 2026Sanara MedTech Inc.MedtechMiMedx Group, Inc.$303M$33โ€”PendingDEFM14A
Sep 3, 2026Integer Holdings CorpMedtechArmstrong Parent, Inc.$4.3B$127โ€”Closed Nov 17DEFM14A
Aug 26, 2026Lantheus Holdings, Inc.Curium$6.7B$102.50 + $12 CVRโ€”PendingDEFM14A
Aug 14, 2026LogicMark, Inc.MedtechLangham Project, LLC$1M$1.31โ€”PendingDEFM14A
Aug 11, 2026Theravance Biopharma, Inc.Zymeworks Inc.$883M$17โ€”Closed Sep 23DEFM14A
Aug 10, 2026BIO-TECHNE CorpMerck KGaA, Darmstadt, Germany$11.4B$73โ€”PendingDEFM14A
Jul 30, 2026AtaiBeckley Inc.Eli Lilly and Company$2.5B$6.75 + $2.50 CVRโ€”Closed Sep 11DEFM14A
Jul 27, 2026Forte Biosciences, Inc.argenx$2.2B$77DermatologyClosed Aug 27Schedule TO
Jul 21, 2026Crinetics Pharmaceuticals, Inc.Vertex Pharmaceuticals$9.0B$85Metabolic and endocrineClosed Sep 1DEFM14A
Jul 21, 2026Senti Biosciences Holdings, Inc.โ€”Not statedโ€”โ€”PendingDEFM14A
Jul 2, 2026Apogee Therapeutics, Inc.AbbVie Inc.Not stated$135.11ImmunologyClosed Sep 3DEFM14A
Jun 18, 2026Amneal Pharmaceuticals, Inc.โ€”Not statedโ€”โ€”PendingDEFM14A
Jun 9, 2026Nuvalent, Inc.Gsk$10.6B$124OncologyClosed Jul 15Schedule TO
Jun 1, 2026Organon & Co.Sun Pharma$3.7B$14ImmunologyPendingDEFM14A
May 29, 2026Esperion Therapeutics, Inc.Essence Parent Inc.$813M$3.16Metabolic and endocrineClosed Jul 13DEFM14A
May 29, 2026Avanos Medical, Inc.MedtechA-AV Holdco I, Inc.$1.2B$25โ€”Closed Jul 27DEFM14A
May 28, 2026Catalyst Pharmaceuticals, Inc.Angelini Pharma S.p.A.$3.9B$31.50NeurologyClosed Jul 15DEFM14A
May 15, 2026Cumberland Pharmaceuticals IncApotex$100Mโ€”โ€”PendingDEFM14A
Apr 29, 2026KalVista Pharmaceuticals, Inc.Chiesi Farmaceutici S.p.A.$1.9B$27โ€”Closed Jun 11Schedule TO
Apr 17, 2026Centessa Pharmaceuticals plcEli Lilly and Company$5.9B$38 + $9 CVRโ€”Closed Jun 24DEFM14A
Apr 9, 2026Assertio Holdings, Inc.Zydus Lifesciences Ltd.$163M$23.50โ€”Closed Jul 7Schedule TO
Apr 6, 2026Soleno Therapeutics IncNeurocrine Biosciences, Inc.$2.9B$53NeurologyClosed May 18Schedule TO
Apr 1, 2026Penumbra IncMedtechBoston Scientific Corporation$14.7B$374โ€”PendingDEFM14A
Mar 31, 2026Apellis Pharmaceuticals, Inc.Biogen Inc.$5.8B$41 + $4 CVRRenal and urologyClosed May 14Schedule TO
Mar 30, 2026Kezar Life Sciences, Inc.Aurinia Pharma U.S., Inc.$55M$6.96ImmunologyClosed May 11Schedule TO
Mar 25, 2026Terns Pharmaceuticals, Inc.Merck$6.7B$53โ€”Closed May 5Schedule TO
Mar 18, 2026Masimo CorpMedtechDanaher Corporation$9.4B$180โ€”Closed Jun 10DEFM14A
Feb 26, 2026Fonar CorpMedtechโ€”Not stated$19โ€”Closed Jun 3DEFM14A
Feb 23, 2026Arcellx, Inc.Gilead Sciences, Inc.$7.8B$115 + $5 CVRโ€”Closed Apr 28Schedule TO
Jan 30, 2026BioAtla, Inc.โ€”Not statedโ€”OncologyPendingDEFM14A
Jan 28, 2026Lifeward Ltd.MedtechOramed Pharmaceuticals Inc.Not statedโ€”โ€”PendingDEFM14A
Jan 22, 2026Ventyx Biosciences, Inc.Eli Lilly and Company$999M$14DermatologyClosed Mar 4DEFM14A
Jan 21, 2026Amicus Therapeutics, Inc.BioMarin Pharmaceutical Inc.$4.5B$14.50โ€”Closed Apr 27DEFM14A
Jan 21, 2026Lisata Therapeutics, Inc.Kuva Labs Inc.$32M$4 + $3 CVROncologyPendingSchedule TO
Jan 20, 2026RAPT Therapeutics, Inc.Gsk$2.2B$58โ€”Closed Mar 3Schedule TO
Dec 29, 2025Exact Sciences CorpTools and diagnosticsAbbott Laboratories$19.9B$105โ€”Closed Mar 23DEFM14A
Dec 29, 2025Dynavax Technologies CorpSanofi$2.3B$15.50โ€”Closed Feb 10Schedule TO

A listed company is bought by a tender offer (Schedule TO-T, filed by the buyer) or a merger its holders vote on (a DEFM14A proxy); both name the company and the buyer. Included: companies whose SEC industry code is drugs and biologics (2833 to 2836), devices (3841 to 3845, 3851) or research tools and labs (3826, 8731, 8071). A reverse merger, where a private company takes over a listed one, is left out. The value is the transaction value from the filing-fee table when there is one, else the value the filing states, else the price per share times the shares outstanding. A model reads the buyer, the price and any contingent value right from the opening of the offer or proxy, and a fact is kept only when it quotes the filing word for word. Closed means the company later delisted (Form 25) or deregistered (Form 15). Private companies come from releases since Nov 10, 2026. Disease area is the MeSH branch of most of the company's trials on ClinicalTrials.gov. Venture rounds and IPOs are on Biotech funding. Refreshed weekly. SEC EDGAR (Schedule TO-T, DEFM14A, Forms 25 and 15), PR Newswire, Business Wire and ClinicalTrials.gov ยท Updated Nov 19, 2026

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.